Browse by author
Lookup NU author(s): Professor Stephen Rushton
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 British Veterinary AssociationBackground: Metastatic disease is frequently present at the time of diagnosis of canine thyroid carcinoma; however, utilisation of computed tomography (CT) alone for staging pre-treatment has been rarely reported in the veterinary literature. Methods: The aims of this retrospective study were to stage affected dogs using CT findings of the cervical and thoracic regions, combined with histopathology/cytology results, in order to assess whether metastatic disease/WHO staging was of prognostic significance. Results: Fifty-eight dogs were included in the study. Classification of cases into WHO stages I, II, III and IV were 10%, 50%, 9% and 31%, respectively. No statistically significant effect of WHO stage classification on overall survival/follow-up time was found (P =.576). Surgery resulted in a statistically significant increase in overall survival/follow-up time (P <.01). There was no statistically significant effect on overall survival/follow-up time in dogs that received medical therapy, either as sole therapy or as an adjunctive post-surgery (P =.198). Conclusion: In summary, this study documents the metastatic rate of canine thyroid carcinoma using CT for staging pre-treatment. Staging utilising CT revealed a higher distant metastatic rate in dogs with thyroid carcinoma when compared to historical studies using different imaging techniques. As long-term outcomes are possible for cases with advanced disease, surgical intervention could still be considered.
Author(s): Giannasi C, Rushton S, Rook A, Steen NVD, Venier F, Ward P, Bell R, Trevail T, Lamb V, Eiras A, Ellis J, Roberts E
Publication type: Article
Publication status: Published
Journal: Veterinary Record
Online publication date: 07/02/2021
Acceptance date: 03/12/2020
ISSN (print): 0042-4900
ISSN (electronic): 2042-7670
Publisher: John Wiley and Sons Inc
Altmetrics provided by Altmetric